CA2697621C - Method of efficiently establishing induced pluripotent stem cells - Google Patents
Method of efficiently establishing induced pluripotent stem cells Download PDFInfo
- Publication number
- CA2697621C CA2697621C CA2697621A CA2697621A CA2697621C CA 2697621 C CA2697621 C CA 2697621C CA 2697621 A CA2697621 A CA 2697621A CA 2697621 A CA2697621 A CA 2697621A CA 2697621 C CA2697621 C CA 2697621C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- oct3
- cell
- myc
- sox2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title claims abstract description 7
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 78
- 230000008672 reprogramming Effects 0.000 claims abstract description 75
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 71
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 50
- 238000012258 culturing Methods 0.000 claims abstract description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 113
- 229910052760 oxygen Inorganic materials 0.000 claims description 110
- 239000001301 oxygen Substances 0.000 claims description 110
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 106
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 76
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 71
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 71
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 69
- 239000000126 substance Substances 0.000 claims description 59
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 52
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 229960000604 valproic acid Drugs 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 description 373
- 108090000623 proteins and genes Proteins 0.000 description 86
- 239000005090 green fluorescent protein Substances 0.000 description 48
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 45
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 45
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 40
- 208000015181 infectious disease Diseases 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 239000002609 medium Substances 0.000 description 27
- 239000013598 vector Substances 0.000 description 27
- 238000004113 cell culture Methods 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 238000012546 transfer Methods 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 16
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- -1 13111-tubulin Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 206010043276 Teratoma Diseases 0.000 description 10
- 210000000981 epithelium Anatomy 0.000 description 10
- 101150111214 lin-28 gene Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000010186 staining Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229950010131 puromycin Drugs 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 101150099612 Esrrb gene Proteins 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- 101000971801 Homo sapiens KH domain-containing protein 3 Proteins 0.000 description 4
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 4
- 102100021450 KH domain-containing protein 3 Human genes 0.000 description 4
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 101100404103 Mus musculus Nanog gene Proteins 0.000 description 4
- 101100137157 Mus musculus Pou5f1 gene Proteins 0.000 description 4
- 101100094847 Mus musculus Slc22a3 gene Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 3
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 102100037124 Developmental pluripotency-associated 5 protein Human genes 0.000 description 2
- 101150033269 ESRRG gene Proteins 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 2
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 101000669432 Homo sapiens Transducin-like enhancer protein 1 Proteins 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 2
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 2
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 101150001847 Sox15 gene Proteins 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 101710101305 Transducin-like enhancer protein 1 Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 230000000431 effect on proliferation Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 102000048971 human GDF3 Human genes 0.000 description 2
- 102000053563 human MYC Human genes 0.000 description 2
- 102000054063 human TLE1 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007959 normoxia Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical group C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- JUNHQBJCWZVSAT-BQYQJAHWSA-N (e)-n-hydroxy-3-[1-methyl-4-(4-methylbenzoyl)pyrrol-2-yl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=CN(C)C(\C=C\C(=O)NO)=C1 JUNHQBJCWZVSAT-BQYQJAHWSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- GEBBCNXOYOVGQS-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](NO)O1 GEBBCNXOYOVGQS-BNHYGAARSA-N 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000804949 Mus musculus Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 102220595793 Myc proto-oncogene protein_T58A_mutation Human genes 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 101150024531 Slc7a1 gene Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 230000001155 adrenomedullary effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 102220283058 rs1555526832 Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003172 sustentacular cell Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8484208P | 2008-07-30 | 2008-07-30 | |
| US61/084,842 | 2008-07-30 | ||
| US14117708P | 2008-12-29 | 2008-12-29 | |
| US61/141,177 | 2008-12-29 | ||
| US20393108P | 2008-12-30 | 2008-12-30 | |
| US61/203,931 | 2008-12-30 | ||
| PCT/JP2009/063906 WO2010013845A1 (en) | 2008-07-30 | 2009-07-30 | Method of efficiently establishing induced pluripotent stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2697621A1 CA2697621A1 (en) | 2010-02-04 |
| CA2697621C true CA2697621C (en) | 2017-01-17 |
Family
ID=41610532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2697621A Active CA2697621C (en) | 2008-07-30 | 2009-07-30 | Method of efficiently establishing induced pluripotent stem cells |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9528092B2 (OSRAM) |
| EP (1) | EP2307539B1 (OSRAM) |
| JP (1) | JP5562231B2 (OSRAM) |
| KR (1) | KR101685209B1 (OSRAM) |
| CN (2) | CN101848994A (OSRAM) |
| CA (1) | CA2697621C (OSRAM) |
| WO (1) | WO2010013845A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010042490A1 (en) * | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| US10328103B2 (en) | 2009-01-03 | 2019-06-25 | Ray C. Wasielewski | Medical treatment composition comprising mammalian dental pulp stem cells |
| US8470308B2 (en) * | 2009-01-03 | 2013-06-25 | Ray C. Wasielewski | Enhanced medical implant comprising disrupted tooth pulp and tooth particles |
| JP5637354B2 (ja) * | 2009-03-30 | 2014-12-10 | 独立行政法人産業技術総合研究所 | 精製転写因子の調製法と細胞導入技術 |
| WO2011016588A1 (en) | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| US8420352B2 (en) | 2009-08-27 | 2013-04-16 | Synaptic Research, Llc | Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells |
| US20120301438A1 (en) * | 2009-09-14 | 2012-11-29 | The Johns Hopkins University | Reprogramming Blood Cells to Pluripotent and Multipotent Stem Cells |
| WO2011062963A2 (en) * | 2009-11-17 | 2011-05-26 | Vitro Diagnositics, Inc. | Induced puripotent stem cells and related methods |
| US8691574B2 (en) * | 2010-06-15 | 2014-04-08 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| KR101861171B1 (ko) * | 2010-06-18 | 2018-05-31 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 투석된 혈청이 있는 심근세포 배지 |
| EP2647699B1 (en) | 2010-12-03 | 2020-04-01 | Kyoto University | Efficient method for establishing induced pluripotent stem cells |
| CN106893692B (zh) | 2010-12-22 | 2021-11-26 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
| CN107988381B (zh) | 2011-07-25 | 2021-05-28 | 国立大学法人京都大学 | 筛选诱导的多能干细胞的方法 |
| US20140227780A1 (en) * | 2011-10-03 | 2014-08-14 | Nissan Chemical Industries, Ltd. | Method for producing megakaryocytes and/or platelets from pluripotent stem cells |
| JP6162604B2 (ja) | 2011-10-21 | 2017-07-12 | 国立大学法人京都大学 | 層流による多能性維持単一分散細胞培養法 |
| WO2013077423A1 (ja) | 2011-11-25 | 2013-05-30 | 国立大学法人京都大学 | 多能性幹細胞の培養方法 |
| RU2619221C2 (ru) * | 2012-03-28 | 2017-05-12 | Кварримен Корпорейшн | Иммортализованная стволовая клетка и лекарственная композиция и лекарственный препарат, содержащие ее в качестве активного ингредиента |
| EP2853592B1 (en) | 2012-05-23 | 2019-02-20 | Kyoto University | Highly efficient method for establishing artificial pluripotent stem cell |
| WO2013183718A1 (ja) * | 2012-06-06 | 2013-12-12 | 国立大学法人京都大学 | スクリーニング方法、タンパク質の不安定性及び／又は安定性を誘導する物質、及び、タンパク質の活性評価 |
| CA2895791A1 (en) | 2013-01-25 | 2014-07-31 | Xcell Biosciences, Inc. | Methods, compositions, kits, and systems for selective enrichment of target cells |
| JP6495658B2 (ja) | 2013-02-08 | 2019-04-03 | 国立大学法人京都大学 | 巨核球及び血小板の製造方法 |
| WO2014136581A1 (ja) | 2013-03-06 | 2014-09-12 | 国立大学法人京都大学 | 多能性幹細胞の培養システム及び多能性幹細胞の継代方法 |
| US9790468B2 (en) | 2013-03-15 | 2017-10-17 | Avita Iinternational Ltd. | Multifunctional immature dental pulp stem cells and therapeutic applications |
| EP2977449B1 (en) | 2013-03-21 | 2020-02-26 | Kyoto University | Pluripotent stem cell for neuronal differentiation induction |
| WO2014157257A1 (ja) | 2013-03-25 | 2014-10-02 | 公益財団法人先端医療振興財団 | 細胞の選別方法 |
| JP6461787B2 (ja) | 2013-04-12 | 2019-01-30 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
| JP6429280B2 (ja) | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | 効率的な心筋細胞の誘導方法 |
| US9796962B2 (en) | 2013-08-07 | 2017-10-24 | Kyoto University | Method for generating pancreatic hormone-producing cells |
| SG11201601720RA (en) | 2013-09-05 | 2016-04-28 | Univ Kyoto | New method for inducing dopamine-producing neural precursor cells |
| JP6635505B2 (ja) | 2013-11-01 | 2020-01-29 | 国立大学法人京都大学 | 新規軟骨細胞誘導方法 |
| FR3016372B1 (fr) * | 2014-01-13 | 2018-01-19 | Centre Leon Berard | Procede de preparation de cellules pluripotentes induites |
| EP3093023B1 (en) * | 2014-01-24 | 2020-11-04 | Quarrymen & Co. Inc. | Pharmaceutical composition for cancer treatment |
| CN104894060B (zh) * | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | 诱导体细胞转分化为神经干细胞的方法及其应用 |
| SG10201807292YA (en) * | 2014-03-04 | 2018-09-27 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| US12241089B2 (en) | 2014-07-18 | 2025-03-04 | Kyoto University | Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells |
| US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
| AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
| US11898163B2 (en) | 2016-04-22 | 2024-02-13 | Kyoto University | Method for producing dopaminergic neuron progenitor cell |
| WO2017223199A1 (en) * | 2016-06-22 | 2017-12-28 | Xcell Biosciences, Inc. | Methods for increasing cell culture transfection efficiency and cellular reprogramming |
| JP7088564B2 (ja) | 2016-11-10 | 2022-06-21 | ヴィアサイト，インコーポレイテッド | 細胞送達装置におけるｐｄｘ１膵臓内胚葉細胞及びその方法 |
| EP3824912A4 (en) | 2018-07-19 | 2022-04-20 | Kyoto University | PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE |
| US20210332329A1 (en) | 2018-07-23 | 2021-10-28 | Kyoto University | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
| EP3900787A4 (en) | 2018-12-21 | 2022-02-23 | Kyoto University | LUBRICIN-LOCALIZED CARTILE-LIKE TISSUE, METHOD OF MANUFACTURE THEREOF AND COMPOSITION THEREOF FOR TREATMENT OF ARTICULATE-CARTILAGE DEFECTS |
| CA3139836A1 (en) * | 2019-05-09 | 2020-11-12 | Figene, Llc | Fibroblast generated patient-specific vaccines |
| EP3969571A4 (en) | 2019-05-14 | 2023-05-24 | Aleph Farms Ltd. | AGGREGATES OF PLURIPOTENT CELLS AND THEIR USE |
| EP4074321A4 (en) | 2019-12-12 | 2024-01-03 | National University Corporation Chiba University | Freeze-dried preparation containing megakaryocytes and platelets |
| EP4180516A4 (en) | 2020-07-13 | 2024-01-17 | Kyoto University | SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS |
| JPWO2022019152A1 (OSRAM) | 2020-07-20 | 2022-01-27 | ||
| JPWO2023153464A1 (OSRAM) | 2022-02-09 | 2023-08-17 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1025204A4 (en) | 1997-10-23 | 2001-02-28 | Geron Corp | Methods and materials for the growth of primate-derived primordial stem cells |
| WO2001096532A2 (en) * | 2000-06-15 | 2001-12-20 | Tanja Dominko | Method of generating pluripotent mammalian cells by fusion of a cytoplast fragment with a karyoplast |
| EP2457999B1 (en) | 2002-12-16 | 2018-10-17 | Technion Research & Development Foundation Ltd. | Culture medium for pluripotent stem cells |
| WO2006019366A1 (en) | 2003-03-28 | 2006-02-23 | Wisconsin Alumni Research Foundation | Physiochemical culture conditions for embryonic stem cells |
| US7442548B2 (en) | 2004-09-08 | 2008-10-28 | Wisconsin Alumni Research Foundation | Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid |
| EP1841857A1 (en) | 2004-12-30 | 2007-10-10 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
| KR101420740B1 (ko) | 2005-12-13 | 2014-07-17 | 교또 다이가꾸 | 핵초기화 인자 |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| DK2137295T3 (en) | 2007-01-04 | 2018-06-25 | Karl Tryggvason | Use of a composition and method for enabling proliferation of pluripotent stem cells |
| EP2137296A2 (en) * | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| US20120282229A1 (en) | 2007-08-01 | 2012-11-08 | Christian Kannemeier | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
| US20110033931A1 (en) | 2007-11-29 | 2011-02-10 | Children's Hospital Of Orange County | De-differentiation of human cells |
| US9290740B2 (en) | 2008-03-07 | 2016-03-22 | Worcester Polytechnic Institute | Use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells |
| ES2722198T3 (es) | 2008-05-02 | 2019-08-08 | Univ Kyoto | Método de reprogramación nuclear |
| WO2009142717A2 (en) * | 2008-05-19 | 2009-11-26 | President And Fellows Of Harvard College | Methods and products for dedifferentiation of cells |
| KR101606943B1 (ko) | 2008-06-27 | 2016-03-28 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
| US20110231944A1 (en) | 2008-09-04 | 2011-09-22 | Riken | B cell-derived ips cells and application thereof |
| ES2549155T3 (es) | 2008-09-08 | 2015-10-23 | Riken | Células iPS obtenidas a partir de células NKT y células NKT obtenidas a partir de las mismas |
| CN101492676B (zh) * | 2008-09-16 | 2011-02-16 | 中国科学院广州生物医药与健康研究院 | 用脑膜细胞生成诱导的多能性干细胞的方法及其用途 |
| WO2011016588A1 (en) | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
-
2009
- 2009-07-30 EP EP09803075.2A patent/EP2307539B1/en active Active
- 2009-07-30 KR KR1020107002641A patent/KR101685209B1/ko active Active
- 2009-07-30 JP JP2010506476A patent/JP5562231B2/ja active Active
- 2009-07-30 CN CN200980100065A patent/CN101848994A/zh active Pending
- 2009-07-30 CA CA2697621A patent/CA2697621C/en active Active
- 2009-07-30 CN CN201611216942.9A patent/CN107012123A/zh active Pending
- 2009-07-30 US US12/672,222 patent/US9528092B2/en active Active
- 2009-07-30 WO PCT/JP2009/063906 patent/WO2010013845A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110036523A (ko) | 2011-04-07 |
| CN101848994A (zh) | 2010-09-29 |
| EP2307539A1 (en) | 2011-04-13 |
| US20110039338A1 (en) | 2011-02-17 |
| US9528092B2 (en) | 2016-12-27 |
| WO2010013845A1 (en) | 2010-02-04 |
| EP2307539A4 (en) | 2012-10-24 |
| JP2011529329A (ja) | 2011-12-08 |
| CA2697621A1 (en) | 2010-02-04 |
| EP2307539B1 (en) | 2014-11-19 |
| CN107012123A (zh) | 2017-08-04 |
| JP5562231B2 (ja) | 2014-07-30 |
| KR101685209B1 (ko) | 2016-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2697621C (en) | Method of efficiently establishing induced pluripotent stem cells | |
| US8951801B2 (en) | Method for making IPS cells | |
| US8927277B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| CA2695522C (en) | Method of nuclear reprogramming | |
| US9637732B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| US10077429B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| AU2008360135A1 (en) | Efficient method for establishing induced pluripotent stem cells | |
| EP2480657B1 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| WO2017010080A1 (ja) | 高品質なｉＰＳ細胞の製造方法 | |
| WO2011055851A1 (en) | Method of efficiently establishing induced pluripotent stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140723 |